Ascletis to Present Study Results at ObesityWeek 2025
Ascletis Pharma Inc. will present study results at ObesityWeek 2025 in Atlanta, Georgia.
- ASC30 Oral Tablet
- ASC30 Injection
- Combination of ASC31 and ASC47
A full analysis of 28-Day MAD Study of Oral GLP-1R Biased Small Molecule Agonist ASC30 for obesity
Presentation Time: November 4, 2025, 7:30 p.m.-8:30 p.m.
Author's summary: Ascletis presents obesity study results.
More News
- Leptin neural circuit restores balance after anxiety upsets it
- The Founding of New York - Historic UK
- Jensen Ackles back on 'Tracker' 3.2 to amp up the suspense
- Novartis Agrees to Acquire Avidity Biosciences
- Pirates Listed as Potential Fit for Trent Grisham, Luis Arráez and Other Top Free Agents
- West Indies ease past Bangladesh in first T20I
- READY, FIRE, AIM: Fly Me to the Moon – Pagosa Daily Post News Events & Video for Pagosa Springs Colorado
- Novartis Enters $12 Billion Definitive Merger Agreement to Acquire Avidity Biosciences | PharmExec
- Three resilient UK multinationals global managers are excited about | Trustnet
- Liam Hemsworth vs. Gabriella Brooks: Who Has the Higher Net Worth?